Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gabriele Wessling"'
Autor:
Jan Braess, Frank Ueckeroth, Diana S.Y. Abdulla, Carina Heydt, Anna-Kristina Eisert, Frank Beckers, Wolfram Meister, Hans-Joachim Kabitz, Johann Lorenzen, Monika Serke, Sabine Merkelbach-Bruse, Sebastian Michels, Jana Fassunke, Florian Kron, A. Meyer, Gabriele Wessling, Lucia Nogova, Bernhard Schaaf, Juliane Sueptitz, Matthias Scheffler, Carsten Schaepers, Sophia Koleczko, Reinhard Buettner, Clemens Schulte, Britta Kaminsky, Richard F. Riedel, Anna Kron, Stefan Krueger, Wolfgang Schulte, Joachim Lorenz, Michael Hamm, Kato Kambartel, Anne M. Schultheis, Christian Grohé, Jürgen Wolf, Lea Ruge, Jutta Kappes, Jens Panse, Niels Reinmuth, Rieke Fischer
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(4)
Robust data on the outcome of MET-aberrant NSCLC with nontargeted therapies are limited, especially in consideration of the heterogeneity of MET-amplified tumors (METamp).A total of 337 tumor specimens of patients with MET-altered Union for Internati
Autor:
Gabriele Wessling, Gustav Quade, Annegret Quade, Katja Monreal, J.A. Kurbacher, Susanne Herz, Christian M. Kurbacher, Carsten Bartling
Publikováno v:
Journal of Clinical Oncology. 34:e23053-e23053
e23053Background: This translational study sought to elucidate the incidence of abnormal sHER2 values in a real-world population of breast cancer (BC) patients (pts) with primary and recurrent dise...
Publikováno v:
Journal of Clinical Oncology. 31:e16533-e16533
e16533 Background: Bevacizumab (Bev) is approved for the therapy (Tx) of primary and platinum-sensitive recurrent Mullerian tract cancers (MTC) such as ovarian (OC), fallopian tube (FTC), type II endometrial (EC-II), and peritoneal papillary-serous c